-
Mashup Score: 11
This cohort study assesses the increase in second primary malignant neoplasms and T-cell malignant neoplasm cases associated with chimeric antigen receptor–T cells.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4#CARTcell - Healthcare Social Media Analytics and Transcripts - 2 month(s) ago
What is #CARTcell? Cancer Immunotherapy, CAR T-Cell Therapy, CAR-T cells, Chimeric Antigen Receptors, immunotherapy, T-Cells. Healthcare Social Media Hashtag. Real-time Analytics.
Source: www.symplur.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7
Genetic disruption of SUV39H1 enhances the expansion, long-term function, and antitumor efficacy of human CAR T cells in both leukemia and prostate tumor models, suggesting that this strategy could improve adoptive cell therapies in cancer.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
European Journal of Haematology is an international haematology journal for basic & clinical research, covering all diseases of the blood, vascular & lymphatic tissue.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
In this latest episode of ASTCT Talks, Misty Evans, DNP, APRN, CPNP-AC, sits down with Flora Stondell, FNP, to delve into the intricacies of University of California, Davis’ (UC…
Source: nucleus.astct.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5Mediport use as an acceptable standard for CAR T cell infusion - 6 month(s) ago
IntroductionMediport use as a clinical option for the administration of chimeric antigen receptor T cell (CAR T cell) therapy in patients with B-cell malignancies has yet to be standardized. Concern for mediport dislodgement, cell infiltration, and ineffective therapy delivery to systemic circulation has resulted in variable practice with intravenous administration of CAR T cell therapy. With CAR T cell commercialization, it is important to establish practice standards for CAR T cell delivery. We conducted a study to establish usage patterns of mediports in the clinical setting and provide a standard of care recommendation for mediport use as an acceptable form of access for CAR T cell infusions. MethodsIn this retrospective cohort study, data on mediport use and infiltration rate was collected from a survey across 34 medical centers in the Pediatric Real-World CAR Consortium, capturing 504 CAR T cell infusion routes across 489 patients. Data represents the largest, and to our knowledg
Source: www.frontiersin.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2Program Guide – ASCO Meeting Program Guide - 6 month(s) ago
Jennifer M. Ahlstrom HealthTree Foundation, Lehi, UT Jennifer M. Ahlstrom, Dee Lin, Nathan W. Sweeney, Bingcao Wu, Katharine Gries, Nina Kim, Saurabh Patel, Douglas W. Sborov, Jesus G. Berdeja, Larry D. Anderson, Jr, Jinhai Huo, Jay R Hydren HealthTree Foundation, Lehi, UT, Janssen Scientific Affairs, LLC, Horsham, PA, Janssen Global Services, LLC, Raritan, NJ, Janssen US Oncology Medical Affairs, Horsham, PA, The University of Utah Huntsman Cancer Institute, Salt Lake City, UT, Sarah Cannon Research
Source: meetings.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 6Extending efficacy for CAR T-cell therapies - 6 month(s) ago
Fred Hutchinson Cancer Center immunotherapy researcher Dr. Shivani Srivastava received an NCI MERIT Award to study T-cell reservoirs to help improve CAR T-cell therapies against solid tumors.
Source: www.fredhutch.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3
Lack of manufacturing slots, viral vector scarcity among issues for patients with multiple myeloma.
Source: aacrjournals.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Extending efficacy for CAR T-cell therapies - 6 month(s) ago
Fred Hutchinson Cancer Center immunotherapy researcher Dr. Shivani Srivastava received an NCI MERIT Award to study T-cell reservoirs to help improve CAR T-cell therapies against solid tumors.
Source: www.fredhutch.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Increased reporting risk of second primary malignancy including T-cell malignancies following #CARTcell. Great 🧵by @KRejeski on our recent work in @JAMAOnc https://t.co/eTmng68Dam. 🙏Kai, Ryan Storgard, @Adam_goldman_ @DrMiguelPerales https://t.co/hc0mlkoYZD